Bayer to manufacture CureVac COVID-19 vaccine

By Georgia Wilson
Share
German multinational pharmaceutical company - Bayer - announce its plans to manufacture the CureVac, mRNA COVID-19 vaccine...

Alongside the German government and Franz-Werner Haas, Chief Executive Officer of CureVac N.V., Stefan Oelrich, Member of the Board of Management, Bayer AG and President of the Bayer’s Pharmaceuticals Division announced plans for the pharmaceutical company to manufacture the CureVac mRNA COVID-19 vaccine in Germany.

“Following discussions with the German government it has become clear that current manufacturing capacities for vaccines need to be increased, particularly for potential variants of the SARS-CoV-2 virus. This includes the need to expand production capacity as well as related manufacturing expertise in Germany. We at Bayer will contribute even further by making more vaccines available to help fight the pandemic,” commented Oelrich.

Bayer will be providing an additional 160 million doses of CureVac’s vaccine in 2022 to further expand their supply network and overall capacity by using the manufacturing network of Bayer. “First commercial product from this expansion may already be available towards the end of this year,” added Oelrich.

Bayer and CureVac’s partnership

The latest plans announced by Bayer furthers the pharmaceutical company’s current support it is providing CureVac which include, the development, supply and key territory operations of CureVac’s vaccine candidate.

Bayer provides CureVac with “its expertise and established infrastructure in areas such as clinical operations, regulatory affairs, pharmacovigilance, medical information, supply chain management as well as support with country operations within the European Union and selected additional markets,” said Oelrich.

Since forming its alliance with CureVac in early 2021, Bayer has been striving to further contribute to CureVac’s operations by providing end-to-end manufacturing.

“Although we have not previously produced vaccines, we hold strong expertise in the development of biotech products [...] I am glad to report today that we have the necessary skills and capabilities at Bayer to manufacture CureVac’s mRNA-based vaccine,” stated Oelrich.

For more information on manufacturing topics - please take a look at the latest edition of Manufacturing Global.

Follow us on LinkedIn and Twitter.

Share

Featured Articles

Achieve Digital Manufacturing Continuity with DELMIA

Discover how to digitally connect your operations in Dassault Systèmes's Delmia's webinar 'Achieve Digital Continuity: Connect Engineering to Operations'

Trump Tariffs Spark Trade War: The Manufacturing Impact

As US President Donald Trump's tariffs on Mexican, Chinese and Canadian goods go ahead, these three nations have responded with measures of their own

EXIGENCE: Curbing Green Impact of Telecoms Manufacturing

Ten organisations have come together to create EU Tech Consortium EXIGENCE, designed to combat telecoms carbon footprint and the environmental impact of 6G

Ranking the Top Five Manufacturing Stories of the Week

Production & Operations

JLR Boosts Bespoke Offerings via Sustainable Paint Evolution

Production & Operations

BIC's Model for Global and Operational Manufacturing Success

Production & Operations